Chen Bihua's Form 4 filing
BridgeBio Oncology Therapeutics, Inc. (BBOT) · filed Jul 6, 2026
- Accession no.
- 0001213900-26-075538
- Filed
- Jul 6, 2026, 4:34 PM ET
- Trade date
- Jul 1, 2026
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Chen BihuaCIK 0001599214 | Director, 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 1, 2026 | Common Stock | JOtherDisposed | −4,528,186 | $0.00 | $0 | 0 | Indirect | |
| Jul 1, 2026 | Common Stock | JOtherAcquired | +2,692,459 | $0.00 | $0 | 4,879,995 | Indirect | |
| Jul 1, 2026 | Common Stock | JOtherAcquired | +1,704,862 | $0.00 | $0 | 5,010,332 | Indirect | |
| Jul 1, 2026 | Common Stock | JOtherAcquired | +130,865 | $0.00 | $0 | 6,083,221 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.
Remarks
Ms. Chen serves on the Board of Directors of the Issuer. Sponsor and the Cormorant Funds may be deemed to be directors by deputization as a result of the service of Ms. Chen.